Sharp rebound. The announcement of achieving milestones and demand forecasts based on the joint research agreement for the utilization of culture supernatants with AND medical group is considered positive news. The first milestone based on the progress of research in the joint research agreement with AND medical aimed at utilizing culture supernatants produced in the production of regenerative medicine and other products owned by the company has been achieved. Following the one-time payment of 60 million yen at the time of contract signing, we will receive another 60 million yen as compensation for this milestone achievement, with the deposit scheduled for the fourth quarter of the fiscal year ending December 2024.